Skip to content

US · ALKS · BIOTECHNOLOGY

Alkermes plc (ALKS) intrinsic value and stock valuation

$44.94as of 2026-11-21 · Mkt cap 8.32B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Alkermes plc DCF and intrinsic value

InvestorsCraft values ALKS with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ALKS’s statements →

Alkermes plc Graham Number

Graham Number: $19.10d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Dublin, DU D04 C5Y6 alkermes.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$1.48B+7.3% 5y CAGRd
20112025
Net income
$241.7M
20112025
Free cash flow
$480.3M+63.9% 5y CAGRd
20112025
Total equity
$1.82B+11.3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$1.48B$1.56B$1.66B$1.11B$1.17B
Operating income$254M$420.6M$414.1M-$-6.09M$97.8M
Net income$241.7M$367.1M$355.8M-$-158.27M-$-48.17M
EPSd$1.43M$2.17M$2.1M-$-966.59K-$-299.3K
Operating cash flow$520.8M$439.1M$401.4M$21M$101.7M
Capital expenditure-$-40.42M-$-33.48M-$-48.05M-$-38.26M-$-29.02M
Free cash flow$480.3M$405.6M$353.3M-$-17.21M$72.7M
Total assets$2.53B$2.06B$2.14B$1.96B$2.02B
Total debt$70M$75.5M$372.2M$379.4M$416.2M
Net debt-$-1.05B-$-215.61M-$-85.28M$87M$78.7M
Total equity$1.82B$1.46B$1.2B$1.04B$1.11B
Cash and short-term investments$1.32B$751.7M$773.5M$608.5M$536.3M
Income statement
20252024202320222021
Revenue$1.48B$1.56B$1.66B$1.11B$1.17B
Cost of revenue$196.5M$245.3M$253M$218.1M$197.3M
Gross profit$1.28B$1.31B$1.41B$893.7M$976.4M
Research and development expenses$324M$245.3M$270.8M$272.7M$290.9M
Selling, general and administrative expenses$714.5M$645.2M$689.8M$590.8M$549.6M
Other expenses-$-13M$1.1M$35.7M$36.4M$38.2M
Operating expenses$1.03B$891.7M$996.3M$899.8M$878.7M
Cost and expenses$1.22B$1.14B$1.25B$1.12B$1.08B
Interest income$45.3M$42.5M$30.9M$7.63M$2.41M
Interest expense$12.3M$22.6M$23M$13M$11.2M
Depreciation and amortization$27.2M$28.5M$74.9M$77.9M$78.7M
Ebitda$330.9M$494.9M$519.5M$59.8M$177.6M
Operating income$254M$420.6M$414.1M-$-6.09M$97.8M
Total other income/expenses, net$37.5M$23.1M$7.4M-$-25.04M-$-10.02M
Income before tax$291.5M$443.8M$421.5M-$-31.13M$87.7M
Income tax expense$49.8M$71.6M-$-97.64M$2.02M$11.3M
Net income$241.7M$367.1M$355.8M-$-158.27M-$-48.17M
Weighted average shares outstanding$164.7M$165.4M$166.2M$163.7M$160.9M
Weighted average diluted shares outstanding$168.7M$169.2M$169.7M$163.7M$160.9M
Balance sheet
20252024202320222021
Cash and short-term investments$1.32B$751.7M$773.5M$608.5M$536.3M
Net receivables$334M$389.5M$333.2M$296.9M$326.6M
Inventory$196.6M$182.9M$186.4M$181.4M$150.3M
Total current assets$1.93B$1.42B$1.49B$1.13B$1.06B
Property, plant and equipment, net$298.9M$311.8M$318.4M$320.5M$456.7M
Goodwill and intangible assets$83.8M$83.9M$85M$120.7M$166.9M
Long-term investments$140K$73.2M$39.9M$131.6M$229.4M
Total non-current assets$601.1M$640.2M$650.7M$833.7M$962.3M
Total assets$2.53B$2.06B$2.14B$1.96B$2.02B
Accounts payable$108M$45.6M$65.7M$32.8M$55.7M
Short-term debt$6.75M$6.17M$8.75M$12.9M$19.2M
Deferred revenue$0.00$1.25M$2.73M$6.82M$6.34M
Total current liabilities$543.4M$465.2M$520.2M$497.7M$471.3M
Long-term debt$63.3M$69.4M$363.4M$366.6M$397M
Deferred revenue, non-current$0.00$1.25M$4.78M$0.00$11.5M
Total non-current liabilities$167.5M$125.4M$413.3M$422.5M$440.6M
Capital lease obligations$63.3M$75.5M$81.5M$86.2M$120.4M
Total liabilities$711M$590.6M$933.5M$920.2M$911.9M
Common stock$1.81M$1.77M$1.73M$1.69M$1.66M
Retained earnings-$-734.79M-$-976.46M-$-1.34B-$-1.7B-$-1.54B
Accumulated other comprehensive income (loss)-$-2.1M-$-1.97M-$-3.11M-$-10.89M-$-3.72M
Total equity$1.82B$1.46B$1.2B$1.04B$1.11B
Total investments$199.8M$533.7M$355.9M$447.6M$428.2M
Total debt$70M$75.5M$372.2M$379.4M$416.2M
Net debt-$-1.05B-$-215.61M-$-85.28M$87M$78.7M
Cash flow statement
20252024202320222021
Net income$241.7M$367.1M$355.8M-$-158.27M-$-48.17M
Depreciation and amortization$27.2M$28.5M$74.9M$77.9M$78.7M
Stock-based compensation$98.7M$96.6M$100.9M$94.3M$87.6M
Change in working capital$119.1M-$-98.15M-$-36.66M$12.7M-$-25.55M
Accounts receivable$55.5M-$-56.34M-$-44.51M$25.3M-$-38.01M
Inventory-$-14.06M$3.09M-$-2.71M-$-31.02M-$-24.77M
Accounts payable$100.9M-$-57.97M$23M$15.5M$43.3M
Net cash provided by operating activities$520.8M$439.1M$401.4M$21M$101.7M
Investments in property, plant and equipment-$-40.42M-$-33.48M-$-48.05M-$-38.26M-$-29.02M
Acquisitions, net$2.79M$98M$0.00$480K-$-710K
Net cash used for investing activities$295.5M-$-111.31M$53.4M-$-64.54M-$-66.2M
Common stock issued$43.4M$27.6M$16.8M$19.6M$25.3M
Common stock repurchased-$-31.03M-$-200.28M-$-28.47M-$-18.2M-$-16.57M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$12.4M-$-494.14M-$-289.71M-$-1.57M$29.1M
Net change in cash$828.6M-$-166.32M$165M-$-45.07M$64.6M
Cash at end of period$1.12B$291.2M$457.5M$292.5M$337.5M
Operating cash flow$520.8M$439.1M$401.4M$21M$101.7M
Capital expenditure-$-40.42M-$-33.48M-$-48.05M-$-38.26M-$-29.02M
Free cash flow$480.3M$405.6M$353.3M-$-17.21M$72.7M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Alkermes plc

        Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

        CEO
        Richard F. Pops
        Employees
        2.05K
        Beta
        0.29

        Explore

        Frequently asked questions

        What is the intrinsic value of Alkermes plc (ALKS)?

        Alkermes plc (ALKS) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ALKS undervalued?

        ALKS trades at a price of $44.94 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.